As U.S. production investments continue to roll in this year, German pharmaceutical technology specialist LTS Lohmann is joining the fray with a deal to boost its CDMO firepower in the States.
Like several other contract manufacturing expansions announced in the U.S. in recent months, LTS is charting the move by way of acquisition.
LTS—whose bread-and-butter business revolves around developing and manufacturing drug delivery systems—is paying an undisclosed sum to purchase U.S. CDMO Renaissance Lakewood, which itself specializes in nasal sprays and sterile dosage forms.
With the move, LTS will add Renaissance’s facility to its existing roster of production sites in Germany and Israel, as well as the U.S., where it already operates plants in West Caldwell, New Jersey, and St. Paul, Minnesota, according to a Monday press release.
Renaissance was founded in 1979 and is headquartered in Lakewood, New Jersey, where the its production campus is also located. The contractor manufactures unit-dose, bi-dose and multi-dose nasal sprays, as well as small-volume parenteral fill-finish vials, LTS explained in its release. Renaissance also boasts R&D formulation development and spray characterization capabilities through its labs.
Renaissance is joining the fold with roughly 500 employees in tow, said LTS, which noted that the acquisition will expand its drug delivery repertoire and solidify its position in the CDMO market.
Altogether, Renaissance operates more than 310,000 square feet of manufacturing, laboratory and support infrastructure across its New Jersey campus, the company says on its website.
“This acquisition marks a significant step in our strategy to expand our CDMO capabilities and strengthen our position as a global leader in innovative drug delivery solutions,” Bas van Buijtenen, LTS’ chief executive, said in a statement. “Renaissance's expertise in nasal sprays and sterile dosage forms perfectly complements our existing portfolio and will enable us to offer even greater value to our partners and patients worldwide.”
LTS did not disclose the financial terms of the deal. The company expects the Renaissance acquisition to close before the end of November.
News of the LTS acquisition comes as U.S. manufacturing announcements continue to pour in from across the industry. Much of the domestic production push has been fueled by the threat of pharmaceutical import tariffs under the Trump administration. In the case of large, branded drugmakers, those import duty concerns have spurred large investments in greenfield sites around the country.
For CDMOs and producers of generic and biosimilar drugs, however, M&A has frequently proven a popular route to beef up U.S. manufacturing in 2025.
Last week, U.K.-based cell and gene therapy manufacturer OXB—formerly known as Oxford Biomedica—laid out 3.4 million pounds sterling ($4.5 million) to get its hands on a commercial-scale drug factory in North Carolina from fellow CDMO National Resilience.
And late last month, Spanish contractor Laboratorios Farmacéuticos Rovi, known colloquially as Rovi, picked up a production plant in Phoenix, Arizona, from Bristol Myers Squibb. The BMS site in question is equipped to produce potent cytotoxic products, vaccines, obesity drugs, monoclonal antibodies, biosimilars and antibody-drug conjugates.
On the biosimilar front, Korea’s Celltrion has adopted a similar tactic, agreeing to pay 460 billion Korean won ($330 million) for an Eli Lilly drug substance plant in Branchburg, New Jersey, which it claims has “fully eliminated all potential future tariff risks related to its products in the U.S. market.”
Meanwhile, fellow drug delivery specialist Ypsomed—which has made a name for itself designing and manufacturing auto-injectors for liquid drugs—took an alternate approach last week when it revealed plans to spend 200 million Swiss francs ($248 million) to build its first U.S. plant in Holly Springs, North Carolina.
The outpouring of life sciences investment dollars into the U.S. follows an announcement from President Donald Trump in late September, suggesting that companies will face a 100% import tariff on any branded pharmaceutical product shipped from overseas unless those companies are actively building production facilities in the U.S.